Journal
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
Volume 35, Issue 3, Pages 269-274Publisher
WILEY
DOI: 10.1111/ijlh.12072
Keywords
Antiphospholipid antibodies; aPL; dilute russell viper venom time; dRVVT; harmonization; LA; lupus anticoagulants; standardization; utility; variability
Categories
Ask authors/readers for more resources
Antiphospholipid antibodies (aPL) comprise a heterogeneous group of antibodies directed against phospholipids and/or protein-complexed phospholipids. aPL are associated with the serious autoimmune condition antiphosholipid (antibody) syndrome' (APS) and can be defined by either solid-phase' assays that identify anticardiolipin antibodies (aCL) and anti-2-glycoprotein I antibodies (aB2GPI) or liquid-phase' assays that identify lupus anticoagulants (LAs). There is a lack of standardization associated with all forms of aPL testing; however, intermethod and interlaboratory variation using aCL and aB2GPI assays is generally higher than that for LA testing by dRVVT (dilute russell viper venom time) procedures. Compared with either aCL or aB2GPI, LA is also more strongly associated with clinically adverse findings of APS, including thrombosis and obstetric morbidity. This review explores the potential reasons for the above findings and concludes that ultimately a more holistic approach to aPL/APS investigations is needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available